CASI Pharmaceuticals, Inc.

CASI

KYG1933S1012

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 16/07/2024 am IST			5-day change	1st Jan Change
6.25 ^USD	+0.32%		-3.99%	-12.71%

08/07	CASI Pharmaceuticals Names Daniel Lang CFO	MT
08/07	CASI Pharmaceuticals, Inc. Appoints Daniel Lang as CFO	CI

Wei-Wu He proposed to acquire Business Operations in China and all license-in, distribution and related rights in Asia from CASI Pharmaceuticals, Inc. for $40 million.

June 26, 2024

Wei-Wu He proposed to acquire Business Operations in China and all license-in, distribution and related rights in Asia from CASI Pharmaceuticals, Inc. (NasdaqCM:CASI) for $40 million on June 21, 2024.

Latest news about CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals Names Daniel Lang CFO	08/07	MT
CASI Pharmaceuticals, Inc. Appoints Daniel Lang as CFO	08/07	CI
CASI Pharmaceuticals, Inc. Appoints Daniel Lang as Senior Vice President	08/07	CI
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data	27/06	MT
US Futures Trend Lower Pre-Bell as Investors Await Slew of Economic Data	27/06	MT
Top Premarket Gainers	27/06	MT
CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company	27/06	CI
Wei-Wu He proposed to acquire Business Operations in China and all license-in, distribution and related rights in Asia from CASI Pharmaceuticals, Inc. for $40 million.	26/06	CI
CASI Pharmaceuticals Receives Acquisition Proposal for its Entire China Business	26/06	CI
CASI Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from VR Adviser, LLC, Foresite Capital Management, LLC, Panacea Venture Management Co., Ltd.	26/06	CI
Sector Update: Health Care Stocks Advance in Afternoon Trading	15/05	MT
CASI Pharmaceuticals Gets FDA Clearance For Blood Disorder Study	15/05	MT
CASI Pharmaceuticals Receives FDA Clearance on the Investigational New Drug Application for CID-103 in Immune Thrombocytopenia	15/05	CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q1 Revenue $3.4M, vs. Street Est of $12M	14/05	MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Top Midday Gainers	06/03	MT
Looming Employment Report, Powell Testimony Stifle US Equity Futures Pre-Bell	05/03	MT
Rate Cut Uncertainty Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday	05/03	MT
Top Premarket Gainers	05/03	MT
CASI Pharmaceuticals Report Positive Interim Phase 1 Data for BI-1206 in the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China	05/03	CI
CASI Pharmaceuticals, Inc. and CASI Pharmaceuticals Co. Ltd Enter into Certain Agreement with Respect to the Renewal of the Exclusive Distribution Agreement with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd	01/03	CI
Casi Pharmaceuticals Announces First Dose of Folotyn in China	16/02	CI
CASI Pharmaceuticals, Inc. Announces Resignation of Fuqiang Zhang as Chief Commercial Officer	12/02	CI
CASI Pharmaceuticals, Inc. Appoints of Mr. Huang Hai as the Global Chief Commercial Officer	30/01	CI

Chart CASI Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Companyâs Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.

Sector

Pharmaceuticals

Calendar

09/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for CASI Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.25 USD

Average target price

6 USD

Spread / Average Target

-4.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CASI PHARMACEUTICALS, INC.	-12.71%	8.12Cr
ELI LILLY AND COMPANY	+63.05%	86TCr
NOVO NORDISK A/S	+38.89%	63TCr
JOHNSON & JOHNSON	-4.78%	36TCr
MERCK & CO., INC.	+17.52%	32TCr
ABBVIE INC.	+8.43%	30TCr
ASTRAZENECA PLC	+13.72%	24TCr
ROCHE HOLDING AG	+5.07%	23TCr
NOVARTIS AG	+16.34%	23TCr
AMGEN INC.	+14.63%	18TCr

Other Pharmaceuticals

CASI Pharmaceuticals, Inc.

Equities

CASI

KYG1933S1012

Pharmaceuticals

Wei-Wu He proposed to acquire Business Operations in China and all license-in, distribution and related rights in Asia from CASI Pharmaceuticals, Inc. for $40 million.

EPS Revisions